Biodesix has announced an underwritten stock offering of 17,391,832 shares at USD 1.15 per share. The company has also announced a private placement of 760,857 shares of Series A Non-Voting Convertible Preferred Stock at USD 46.00 per share. The gross proceeds from these transactions are expected to be USD 55 million.
The underwritten offering and placement is jointly managed by TD Cowen, William Blair, Canaccord Genuity, and Lake Street Capital Markets. Certain management members, directors, and funds affiliated with these directors are reported to be participating in the private placement. The closing date of the offering is to be around April 9, 2024, subject to customary closing conditions and stockholder approval.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.